Grimes & Company, Inc. Amgen Inc Transaction History

Grimes & Company, Inc.

$3.66 Billion
Q3 2024

A detailed history of Grimes & Company, Inc. transactions in Amgen Inc stock. As of the latest transaction made, Grimes & Company, Inc. holds 91,504 shares of AMGN stock, worth $23.9 Million. This represents 0.81% of its overall portfolio holdings.

Number of Shares

91,504

Previous 93,721 2.37%

Holding current value

$23.9 Million

Previous $29.3 Million 0.68%

% of portfolio

0.81%

Previous 0.88%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 22, 2024	SELL	$309.38 - $337.38 $685,895 - $747,971	-2,217 Reduced 2.37%	91,504 $29.5 Million
Q2 2024 Jul 22, 2024	BUY	$262.75 - $319.31 $151,081 - $183,603	575 Added 0.62%	93,721 $29.3 Million
Q1 2024 Apr 17, 2024	BUY	$268.87 - $324.56 $461,112 - $556,620	1,715 Added 1.88%	93,146 $26.5 Million
Q4 2023 Jan 24, 2024	BUY	$255.7 - $288.46 $165,437 - $186,633	647 Added 0.71%	91,431 $26.3 Million
Q3 2023 Oct 19, 2023	SELL	$218.65 - $271.46 $852,735 - $1.06 Million	-3,900 Reduced 4.12%	90,784 $24.4 Million
Q2 2023 Jul 19, 2023	BUY	$214.27 - $253.37 $55,067 - $65,116	257 Added 0.27%	94,684 $21 Million
Q1 2023 Apr 20, 2023	BUY	$225.79 - $275.2 $668,564 - $814,867	2,961 Added 3.24%	94,427 $22.8 Million
Q4 2022 Jan 25, 2023	BUY	$229.03 - $291.01 $323,848 - $411,488	1,414 Added 1.57%	91,466 $0
Q3 2022 Oct 28, 2022	BUY	$224.46 - $253.15 $131,758 - $148,599	587 Added 0.66%	90,052 $20.3 Million
Q2 2022 Jul 22, 2022	SELL	$230.71 - $256.74 $1.98 Million - $2.2 Million	-8,579 Reduced 8.75%	89,465 $21.8 Million
Q1 2022 May 06, 2022	BUY	$219.27 - $242.57 $1.42 Million - $1.57 Million	6,463 Added 7.06%	98,044 $23.7 Million
Q4 2021 Feb 01, 2022	BUY	$198.88 - $227.6 $367,530 - $420,604	1,848 Added 2.06%	91,581 $20.6 Million
Q3 2021 Nov 08, 2021	BUY	$212.27 - $248.7 $1.03 Million - $1.21 Million	4,869 Added 5.74%	89,733 $19.1 Million
Q2 2021 Aug 04, 2021	BUY	$233.58 - $259.14 $785,295 - $871,228	3,362 Added 4.13%	84,864 $20.7 Million
Q1 2021 May 12, 2021	BUY	$221.91 - $258.6 $3.52 Million - $4.1 Million	15,849 Added 24.14%	81,502 $20.3 Million
Q4 2020 Feb 02, 2021	BUY	$216.38 - $257.67 $2.25 Million - $2.68 Million	10,398 Added 18.82%	65,653 $15.1 Million
Q3 2020 Nov 12, 2020	SELL	$234.65 - $260.95 $491,591 - $546,690	-2,095 Reduced 3.65%	55,255 $14 Million
Q2 2020 Jul 31, 2020	SELL	$197.81 - $242.74 $106,026 - $130,108	-536 Reduced 0.93%	57,350 $13.5 Million
Q1 2020 May 05, 2020	SELL	$182.24 - $241.7 $768,323 - $1.02 Million	-4,216 Reduced 6.79%	57,886 $11.7 Million
Q4 2019 Feb 05, 2020	SELL	$189.21 - $243.2 $382,582 - $491,750	-2,022 Reduced 3.15%	62,102 $15 Million
Q3 2019 Nov 05, 2019	BUY	$174.11 - $208.62 $130,930 - $156,882	752 Added 1.19%	64,124 $12.4 Million
Q2 2019 Jul 30, 2019	BUY	$166.7 - $195.41 $148,196 - $173,719	889 Added 1.42%	63,372 $11.7 Million
Q1 2019 May 02, 2019	BUY	$180.87 - $203.88 $281,795 - $317,645	1,558 Added 2.56%	62,483 $11.9 Million
Q4 2018 Feb 01, 2019	BUY	$178.4 - $208.25 $60,656 - $70,805	340 Added 0.56%	60,925 $11.9 Million
Q3 2018 Nov 09, 2018	BUY	$185.29 - $208.89 $163,425 - $184,240	882 Added 1.48%	60,585 $12.6 Million
Q2 2018 Aug 10, 2018	SELL	$166.05 - $186.51 $199,758 - $224,371	-1,203 Reduced 1.98%	59,703 $11 Million
Q1 2018 May 07, 2018	BUY	$169.43 - $198.0 $1.1 Million - $1.28 Million	6,483 Added 11.91%	60,906 $10.4 Million
Q4 2017 Feb 05, 2018	BUY	$168.79 - $188.59 $106,844 - $119,377	633 Added 1.18%	54,423 $9.46 Million
Q3 2017 Nov 03, 2017	BUY	$167.29 - $191.0 $9 Million - $10.3 Million	53,790	53,790 $10 Million

Others Institutions Holding AMGN

# of Institutions

3,125

Shares Held

409M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $140B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Grimes & Company, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Grimes & Company, Inc. with notifications on news.

Account

Grimes & Company, Inc. Amgen Inc Transaction History